• Profile
Close

SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis

Diabetes, Obesity and Metabolism Apr 20, 2018

Li D, et al. - The efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor were comprehensively investigated by authors in patients with type 2 diabetes mellitus (T2DM). It was observed that the addition of a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by -0.31%, fasting plasma glucose [FPG] by -8.94 mg/dL, total cholesterol (TC) by -1.48% and triglycerides by -3.25%. Data reported similar adverse events for the combination therapy, with the exception of genital infection vs DPP-4 inhibitor and consistent genital infection vs an SGLT2 inhibitor.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay